Forbes May 30, 2024
Robert Hart

Topline

Nestlé is tapping into the lucrative weight loss drug market by catering to customers’ “shifting” nutritional needs, CEO Mark Schneider told CNBC on Thursday, an optimistic pivot from one of the industry’s biggest players in the face of dire early predictions suggesting wildly popular drugs like Ozempic, Mounjaro and Wegovy would take a bite out of the food industry.

Key Facts

Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you’ll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here.

Crucial Quote

Schneider said new lines and offerings targeting GLP-1 drug users will be an “addition” to the food and drinks industry moving forward, rather than its...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Retailer
Walmart is 1st retailer to deliver Rx, general products together
Healthcare CEOs: No time to underestimate retail healthcare
Walmart and Amazon Turn to GenAI and Ditch the ‘Search’ Bar
Walmart bets on multiple AI models with new Wallaby LLM
Walmart Expands Centers of Excellence Benefit To Include All Cancers

Share This Article